fig1

Resistance to cancer immunotherapy in metastatic renal cell carcinoma

Figure 1. Main mechanisms of resistance to current immunotherapy in renal cell carcinoma. The main mechanisms of resistance to current immunotherapy can be divided into three major categories: tumor cell intrinsic factors, patient intrinsic factors and factors related to the tumor microenvironment. Here, some medical interventions to counteract these resistances are described. CAF: cancer associated fibroblasts; CDK4/CDK6: cyclin dependent kinase 4/cyclin dependent kinase 6; CSF1R: colony stimulating factor 1 receptor; CTLA4: cytotoxic T-lymphocyte antigen-4; CTK: cytokine; IDO: indoleamine 2 3-dioxygenase; IFN: interferon; HLA: human leukocyte antigen; ICI: immune checkpoint inhibitor; LAG3: lymphocyte-activation gene 3; MAPK: mitogen-activated protein kinase; MDSCs: myeloid derived suppressor cells; MHC: major histocompatibility complex; PD-1: programmed cell death 1; PTEN: phosphatase and TENsin homolog; RIG-1: retinoic acid-inducible gene 1; STING: stimulator of IFN genes; TAMs: tumor associated macrophages; TIM3: 1-5 T cell immunoglobulin mucin-3; TME: tumor Microenvironment

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/